On November 26, 2024 SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, reported that management will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference, taking place in Coral Gables, Florida on Tuesday, December 3, 2024 at 12:30 p.m. ET (Press release, SpringWorks Therapeutics, NOV 26, 2024, View Source [SID1234648662]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access the live webcast, please visit the Events & Presentations page within the Investors & Media section of the company’s website at View Source A replay of the webcast will be available on SpringWorks’ website for a limited time following the conference.

On November 26, 2024 Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, reported its participation in the following investor conference (Press release, Nkarta, NOV 26, 2024, View Source [SID1234648661]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

7th Annual Evercore HealthCONx Conference
December 4, 2024
2:10 p.m. ET – fireside chat

A simultaneous webcast of the event will be available on the Investors section of Nkarta’s website, www.nkartatx.com, and a replay will be archived on the website for approximately 90 days.

On November 26, 2024 Neurocrine Biosciences, Inc. (Nasdaq: NBIX) reported it will participate at two upcoming investor conferences in December. Chief Executive Officer Kyle Gano, Chief Financial Officer Matt Abernethy, and Vice-President of Investor Relations Todd Tushla will present at (Press release, Neurocrine Biosciences, NOV 26, 2024, View Source [SID1234648660]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The 7th Annual Evercore HealthCONx Conference at 10:50 a.m. Eastern Time on Tuesday December 3, 2024 in Coral Gables, Florida.
Citi’s 2024 Global Healthcare Conference at 1:45 p.m. Eastern Time on Wednesday December 4, 2024 in Miami.
The live presentations will be webcast and may be accessed on Neurocrine Biosciences’ website under Investors at www.neurocrine.com. A replay of the webcasts will be available on the website approximately one hour after the conclusion of the events and will be archived for approximately one month.

On November 26, 2024 Merck (NYSE: MRK), known as MSD outside of the United States and Canada, reported that Robert M. Davis, chairman and chief executive officer, and Dr. Eliav Barr, senior vice president, head of global clinical development and chief medical officer, Merck Research Laboratories, are scheduled to participate in a fireside chat at the Citi 2024 Global Healthcare Conference on Thursday, Dec. 5, 2024, at 8:00 a.m. EST (Press release, Merck & Co, NOV 26, 2024, View Source [SID1234648659]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investors, analysts, members of the media and the general public are invited to listen to a live audio webcast of the presentation at this weblink.

On November 26, 2024 Keros Therapeutics, Inc. ("Keros" or the "Company") (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, reported that Keros’ Chair and Chief Executive Officer Jasbir S. Seehra, Ph.D., will present at the following healthcare conferences (Press release, Keros Therapeutics, NOV 26, 2024, View Source [SID1234648658]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Piper Sandler 36th Annual Healthcare Conference

•Date and Time: Tuesday, December 3, 2024 at 10:30 a.m. Eastern time
•Link: View Source;tp_key=2752037800
•Format: Fireside Chat Presentation

7th Annual Evercore HealthConx Conference

•Date and Time: Wednesday, December 4, 2024 at 3:00 p.m. Eastern time
•Link: View Source
•Format: Fireside Chat Presentation

For each presentation, an archived replay will be accessible in the Investors section of the Keros website at View Source for up to 90 days following the conclusion of each event.